Impact of taxane-based chemotherapeutics on male reproductive function

in Reproduction and Fertility
Authors:
Charvi KanodiaC Kanodia , Edinburgh Medical School , The University of Edinburgh, Edinburgh, United Kingdom of Great Britain and Northern Ireland

Search for other papers by Charvi Kanodia in
Current site
Google Scholar
PubMed
Close
,
Michael P RimmerM Rimmer, MRC Centre for Reproductive Health , The University of Edinburgh, Edinburgh, EH16 4TJ, United Kingdom of Great Britain and Northern Ireland

Search for other papers by Michael P Rimmer in
Current site
Google Scholar
PubMed
Close
,
Kathleen DuffinK Duffin, 3. Biomedical Sciences, The University of Edinburgh, Edinburgh, United Kingdom of Great Britain and Northern Ireland

Search for other papers by Kathleen Duffin in
Current site
Google Scholar
PubMed
Close
, and
Rod T MitchellR Mitchell, Centre for Reproductive Health, Edinburgh, EH164TJ, United Kingdom of Great Britain and Northern Ireland

Search for other papers by Rod T Mitchell in
Current site
Google Scholar
PubMed
Close
View More View Less

Correspondence: Michael Rimmer, Email: michael.rimmer@ed.ac.uk

Lay Summary of Letter

Men and boys with cancer treated with chemotherapy are known to have reduced fertility following their treatment. This is because some chemotherapy drugs can damage the cells in the testicles that make sperm. This study found there is limited information available on the effect of one group of chemotherapy drugs, called taxanes, on testicular function and fertility. More studies are needed to aid clinicians in advising patients on how this taxane-based chemotherapy may affect their future fertility.

 

  • Collapse
  • Expand

     An official journal of

    Society for Reproduction and Fertility